Cardiff Oncology (CRDF) 10-K2021 FY Annual report

Filed: 24 Feb 22, 4:00pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: ablation, accretion, Adam, alkylating, antimicrotubule, aware, Breakthrough, Call, cgmp, checking, chemotherapeutic, compound, COVID, customary, cytotoxic, forfeited, Freestanding, intravenously, Katherine, Kelemen, killing, legacy, Levine, Lonza, MBA, Melanoma, microwave, Monahan, mortality, mPDAC, occupied, Onivyde, onvasertib, Onyvide, ORR, proteasome, RAS, rectal, replicate, resection, resolution, Ruffner, SAU, Schayowitz, Smeal, SPA, Spain, Spanish, strength, succumb, surgical, Task, Tod, unissued, unrealized, Uquifa, vitro, vivo

Removed: accelerated, accumulation, acid, adenosine, adrenocortical, ADT, adult, affiliated, alopecia, Amer, analyze, antiproliferative, antitumor, apparent, array, ASH, assembly, assistant, asymptomatic, ATP, author, AZ, BIDMC, bioavailability, biopsied, blocking, bone, bortezomib, Boston, carcinoma, centrosome, cisplatin, cohort, composed, conference, coupled, David, deacetylase, decitabine, deprivation, detected, DFCI, diagnostic, differentiated, diversification, doxorubicin, effected, Einstein, EIP, enable, EU, exit, expert, expiring, expression, folinic, gelcap, gemcitabine, generation, genetic, genome, GI, Glen, Goodyear, half, HDAC, headcount, Hematologist, hematology, histone, ideal, identifier, indexed, inhibitory, intangible, integrating, integration, intracellular, investigative, Jacob, Johnson, journal, largest, manageable, marrow, maturation, maximal, MDR, MGH, MHS, mild, minimally, moderate, modulate, neutropenia, NHL, noninvasive, occurring, Oncologist, pan, par, participant, pharmacokinetic, PhD, plasma, poster, precisely, prioritized, proceed, professor, progressive, proportion, quick, quickly, ratio, refractory, regain, regression, regulating, relapsed, relief, resistant, retroactively, reverse, scheduling, School, screen, selectivity, sensitive, separation, serve, setting, simple, Specifically, spindle, split, subset, suggest, surgery, symptomatic, tailor, thrombocytopenia, tissue, TNBC, transgenic, transient, transporter, triphosphate, triple, uM, unique, unsatisfactory, utilization, vest, Western, Yale, Zeidan

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

CRDF similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Cardiff Oncology, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mark Erlander, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


2/24/2022			/s/ Mark Erlander

			Mark Erlander
			Chief Executive Officer (Principal Executive Officer)